Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PETER J GAGIANAS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1417975384
CMS profile
154518
Location
MC MURRAY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$67.91

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $67.91 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $34.06 1
Pulmonx Corporation $33.85 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PETER J GAGIANAS

NPI 1417975384 · CMS profile ID 154518

Allopathic & Osteopathic Physicians / Family Medicine

MC MURRAY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417975384?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417975384?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417975384?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PETER J GAGIANAS, NPI 1417975384, CMS profile ID 154518, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417975384?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $67.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pulmonx Corporation $33.8502/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087847331 CMS
ABBVIE INC. $34.0601/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103764124 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $9,087.37 38
PY2020 $27.80 2
PY2021 $501.56 23
PY2022 $376.51 23
PY2024 $67.91 2
PY2025 $20.35 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,125.10 1
PY2022 Principal investigator $27,034.10 4
PY2021 Principal investigator $55,143.92 142
PY2020 Principal investigator $43,019.42 143
PY2019 Principal investigator $58,558.98 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

143 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $900.00 12/22/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325993
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201055
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201057
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201063
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201065
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201071
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201073
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 12/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201076
Principal investigator 1 Novo Nordisk AS $82.00 12/17/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 822173705
Principal investigator 1 Novo Nordisk AS $1,125.00 11/30/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325991
Principal investigator 1 Novo Nordisk AS $41.06 11/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325947
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199356
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199359
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199361
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199369
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199371
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199377
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199381
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199385
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199387
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 11/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737199393
Principal investigator 1 Novo Nordisk AS $75.00 11/18/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325949
Principal investigator 1 Novo Nordisk AS $41.06 11/10/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325953
Principal investigator 1 Esperion Therapeutics, Inc. $3,600.00 11/02/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737197399
Principal investigator 1 Novo Nordisk AS $41.06 11/02/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325951
Principal investigator 1 Novo Nordisk AS $562.50 10/29/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325959
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195931
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195937
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195939
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195945
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195949
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195951
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195957
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195959
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195965
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195968
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195973
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 10/23/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195979
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 09/25/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194755
Principal investigator 1 Novo Nordisk AS $922.50 09/22/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325957
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192033
Principal investigator 1 Esperion Therapeutics, Inc. $563.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192039
Principal investigator 1 Esperion Therapeutics, Inc. $195.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192041
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192045
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192049
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192053
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192057
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192061
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192066
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192070
Principal investigator 1 Esperion Therapeutics, Inc. $338.00 09/21/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737192075
Principal investigator 1 Novo Nordisk AS $82.12 09/17/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325961
Principal investigator 1 Novo Nordisk AS $19.50 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325963
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325965
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325967
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325969
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325971
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325973
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325975
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325977
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325979
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325981
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325983
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325985
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325987
Principal investigator 1 Novo Nordisk AS $180.00 09/15/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325989
Principal investigator 1 Novo Nordisk AS $720.00 08/27/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325955
Principal investigator 1 Novo Nordisk AS $23.46 08/19/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325943
Principal investigator 1 Novo Nordisk AS $23.46 08/10/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325945
Principal investigator 1 Novo Nordisk AS $378.45 07/28/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325849
Principal investigator 1 Novo Nordisk AS $378.45 06/25/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325847
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325851
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325853
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325855
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325857
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325859
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325861
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325863
Principal investigator 1 Novo Nordisk AS $7.60 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325865
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325867
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325869
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325871
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325873
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325875
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325877
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325879
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325881
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325883
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325885
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325887
Principal investigator 1 Novo Nordisk AS $360.00 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325889
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325891
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325893
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325895
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325897
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325899
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325901
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325903
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325905
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325907
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325909
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325911
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325913
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325915
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325917
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325919
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325921
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325923
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325925
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325927
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325929
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325931
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325933
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325935
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325937
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325939
Principal investigator 1 Novo Nordisk AS $20.40 06/08/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325941
Principal investigator 1 Novo Nordisk AS $360.00 05/29/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325803
Principal investigator 1 Novo Nordisk AS $3,250.00 05/28/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
NN9535-4416 No dispute reported 06/30/2026 742325807
Principal investigator 1 Novo Nordisk AS $3,000.00 05/26/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
NN9535-4416 No dispute reported 06/30/2026 742325805
Principal investigator 1 Novo Nordisk AS $75.00 05/01/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325845
Principal investigator 1 Novo Nordisk AS $1,170.00 03/24/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325799
Principal investigator 1 Novo Nordisk AS $130.00 03/24/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325801
Principal investigator 1 Novo Nordisk AS $1,260.00 02/25/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325797
Principal investigator 1 Novo Nordisk AS $59.20 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325815
Principal investigator 1 Novo Nordisk AS $24.40 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325817
Principal investigator 1 Novo Nordisk AS $79.60 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325819
Principal investigator 1 Novo Nordisk AS $150.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325821
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325823
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325825
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325827
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325829
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325831
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325833
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325835
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325837
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325839
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325841
Principal investigator 1 Novo Nordisk AS $90.00 02/13/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325843
Principal investigator 1 Novo Nordisk AS $7.40 02/03/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325809
Principal investigator 1 Novo Nordisk AS $3.05 02/03/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325811
Principal investigator 1 Novo Nordisk AS $9.95 02/03/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325813
Principal investigator 1 Novo Nordisk AS $810.00 01/28/2020 Non-covered Recipient Entity
PRIMARY CARE RESEARCH SOUTH
EX9924-4473 No dispute reported 06/30/2026 742325795